Beyond a Single KRAS Inhibitor: China-Originated Therapeutics and the Rise of Resistance-Directed Combinations
none
2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
none
Abstract Background: Epidermal growth factor receptor (EGFR) mutations are the most clinically actionable oncogenic drivers in Asian patients with non-small-cell lung cancer (NSCLC). The therapeutic landscape has rapidly evolved from single-agent EGFR tyrosine kinase inhibitors (TKIs) to risk-adapted first-line intensi...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.